-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 23, the AstraZeneca China Ecosystem Conference held an opening ceremony and 12 sub-forums in Wuxi with the theme of "creating and predicting the future", covering major therapeutic areas such as tumor, cardiovascular and metabolism, digestion, respiratory and kidney diseases.
Wang Lei, Global Executive Vice President of AstraZeneca, President of International Business and China, attended the conference and delivered a speech, introducing that in the field of precision diagnosis, AstraZeneca will join hands with the world and gene to build a bio-diagnosis innovation center in Guangzhou to carry out clinical testing, Co-create multiple activities such as joint research and external training to jointly promote the further development of precision diagnosis.
Afterwards, the "AstraZeneca S&Gene Guangzhou Biodiagnosis Innovation Center Strategic Cooperation Signing Ceremony" was held at the conference site.
(From left to right: Yang Haiying, Vice President of AstraZeneca China and Head of Medical Affairs Department, Lai Minglong, General Manager of AstraZeneca China, Shao Yang, Founder and CEO of Shihe Gene, Co-founder and Chief Technology Officer of Shihe Gene Wang Xiaonan, Yin Min, General Manager of AstraZeneca China Oncology Business Department, Zhao Nichao, Co-founder and Chief Operating Officer of Shihe Gene)
(From left to right: Yang Haiying, Vice President of AstraZeneca China and Head of Medical Affairs Department, Lai Minglong, General Manager of AstraZeneca China, Shao Yang, Founder and CEO of Shihe Gene, Co-founder and Chief Technology Officer of Shihe Gene Wang Xiaonan, Yin Min, General Manager of AstraZeneca China Oncology Business Department, Zhao Nichao, Co-founder and Chief Operating Officer of Shihe Gene)
Dr.
Shihe Gene has been established for more than seven years.
At present, companion diagnosis is included in the requirements of CDME, and the state also supports companion diagnosis to promote the development of new drugs for targeted drugs.
In terms of advanced tumors, Shihe Gene takes a multi-pronged approach.
In terms of early and mid-term tumors, Shihe Gene launched the Shuning SHIELDING™ solid tumor perioperative whole-process management MRD testing package, hoping to use MRD dynamic monitoring to guide adjuvant medication, prognosis prediction, recurrence risk stratification, and dynamic recurrence monitoring The perioperative full-process management is realized in many aspects, so that more early and mid-term patients can benefit from it.
Strengthening early tumor screening and increasing the early proportion of tumor patients at diagnosis can effectively prolong the overall survival of tumor patients and reduce the family and socio-economic burdens of patients caused by tumor treatment.
In 2020, Shihe Gene initiated a large-scale early screening study called the "Jinling Cohort".
With the conclusion of the strategic cooperation with AstraZeneca, Shihe Gene Southern Center is located in Guangzhou, and has completed the layout of 4 large-scale core laboratories in Beijing, Shanghai, Nanjing, and Guangzhou.
World and Gene GENESEEQ
World and Gene GENESEEQCommitted to clinical tumor precision molecular detection and clinical translational research
Committed to clinical tumor precision molecular detection and clinical translational researchCommitted to providing one-stop NGS platform solutions for hospitals
Committed to providing one-stop NGS platform solutions for hospitalsOwns three international authoritative certifications of CAP/CLIA/ISO15189
Owns three international authoritative certifications of CAP/CLIA/ISO15189Certification business covers tumor tissue and liquid biopsy
Certification business covers tumor tissue and liquid biopsyClinical testing service> 8 years
Clinical testing service> 8 yearsCooperate with Class III A/Tumor Specialty Hospitals> 500
Cooperate with Class III A/Tumor Specialty Hospitals> 500Accumulate the Chinese tumor NGS genome database> 420,000 cases
Accumulate the Chinese tumor NGS genome database> 420,000 casesCumulative published SCI articles>260
Cumulative published SCI articles>260Cumulative Impact Factor (IF)>1700 points
Cumulative Impact Factor (IF)>1700 pointsThe self-developed "EGFR/ALK/ROS1/BRAF/KRAS/HER2 gene mutation detection kit (reversible terminal termination sequencing method)" (National Machinery Note 20183400408) was approved by the NMPA in September 2018, and comprehensively guides lung cancer targeted drugs , The sensitivity is as high as 1%.
The self-developed "EGFR/ALK/ROS1/BRAF/KRAS/HER2 gene mutation detection kit (reversible terminal termination sequencing method)" (National Machinery Note 20183400408) was approved by the NMPA in September 2018, and comprehensively guides lung cancer targeted drugs , The sensitivity is as high as 1%.
